文献速递中枢神经肿瘤放疗

加速超分割放化疗联合替莫唑胺与常规分割放化疗在胶质母细胞瘤回顾性分析中疗效相当

Accelerated hyperfractionated radiochemotherapy with temozolomide is equivalent to normofractionated radiochemotherapy in a retrospective analysis of patients with glioblastoma.
PubMed 文献 · Radiat Oncol · 2019-12-12

该单中心回顾性分析纳入152例新诊断胶质母细胞瘤患者,比较加速超分割放疗(HFRT)54.0 Gy/30次(1.8 Gy每日两次)联合替莫唑胺与常规分割放疗(NFRT)60 Gy/30次联合替莫唑胺的疗效。中位总生存期HFRT组18.5个月,NFRT组24.4个月(p=0.131),多因素分析显示治疗方案与总生存无强关联(p=0.504),支持两者等效的假设。

要点

  • HFRT与NFRT联合替莫唑胺的中位OS分别为18.5个月和24.4个月,差异无统计学意义(p=0.131)。
  • 放疗期间使用地塞米松是总生存的独立不良预后因素(多因素HR 1.95,95%CI 1.21-3.13,p=0.006)。
  • MGMT启动子甲基化阳性及挽救治疗是高度显著的阳性预后因素。

核心结论

  • 回顾性分析支持HFRT与GBM标准治疗方案等效的假设。
  • HFRT可能作为希望缩短放化疗疗程患者的替代选择,但尚未经大型前瞻性随机研究验证。

研究设计与样本

  • 单中心回顾性分析,纳入2004年10月至2018年7月新诊断GBM患者152例。
  • 采用单变量和多变量Cox回归分析(多变量变量经LASSO方法筛选)评估治疗方案等因素与总生存的关联。

主要发现

  • 全队列中位总生存期为20.3个月。
  • NFRT组中位OS为24.4个月,HFRT组为18.5个月(p=0.131)。
  • 单变量回归中放疗期间使用地塞米松对OS有显著负面影响,HR 2.21(95%CI 1.47-3.31,p=0.0001)。
  • 多因素分析校正MGMT启动子甲基化状态、挽救治疗及继发性GBM后,地塞米松仍为不良预后因素,HR 1.95(95%CI 1.21-3.13,p=0.006)。
  • MGMT甲基化阳性及挽救治疗为高度显著的阳性预后因素;治疗方案与OS无强关联(p=0.504)。

临床怎么用

  • 对于希望缩短放化疗疗程的GBM患者,HFRT可作为与标准方案疗效相当的替代选择。
  • 放疗期间应关注糖皮质激素使用对生存的潜在负面影响。
  • 挽救治疗可能改善总生存,应在未来前瞻性试验中进一步评估。

局限性

  • 回顾性分析,样本来自单中心,可能存在选择偏倚。
  • HFRT与标准方案等效的结论尚未经大型前瞻性随机研究证实。
  • 作者计划与其他三级医院进行汇总分析以提高统计可靠性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Current standard of treatment for newly diagnosed patients with glioblastoma (GBM) is surgical resection with adjuvant normofractionated radiotherapy (NFRT) combined with temozolomide (TMZ) chemotherapy. Hyperfractionated accelerated radiotherapy (HFRT) which was known as an option from randomized controlled trials before the temozolomide era has not been compared to the standard therapy in a randomized setting combined with TMZ. METHODS: Data of 152 patients with newly diagnosed GBM treated from 10/2004 until 7/2018 at a single tertiary care institution were extracted from a clinical database and retrospectively analyzed. Thirty-eight patients treated with NFRT of 60 Gy in 30 fractions (34 with simultaneous and 2 with sequential TMZ) were compared to 114 patients treated with HFRT of 54.0 Gy in 30 fraction of 1.8 Gy twice daily (109 with simultaneous and 3 with sequential TMZ). The association between treatment protocol and other variables with overall survival (OS) was assessed using univariable and multivariable Cox regression analysis; the latter was performed using variables selected by the LASSO method. RESULTS: Median overall survival (OS) was 20.3 month for the entire cohort. For patients treated with NFRT median OS was 24.4 months compared to 18.5 months in patients treated with HFRT (p = 0.131). In univariable regression analysis the use of dexamethasone during radiotherapy had a significant negative impact on OS in both patient groups, HR 2.21 (95% CI 1.47-3.31, p = 0.0001). In multivariable analysis adjusted for O6-methylguanine-DNA methyl-transferase (MGMT) promotor methylation status, salvage treatment and secondary GBM, the use of dexamethasone was still a negative prognostic factor, HR 1.95 (95% CI 1.21-3.13, p = 0.006). Positive MGMT-methylation status and salvage treatment were highly significant positive prognostic factors. There was no strong association between treatment protocol and OS (p = 0.504). CONCLUSIONS: Our retrospective analysis supports the hypothesis of equivalence between HFRT and the standard protocol of treatment for GBM. For those patients who are willing to obtain the benefit of shortening the course of radiochemotherapy, HFRT may be an alternative with comparable efficacy although it was not yet tested in a large prospective randomized study against the current standard. The positive influence of salvage therapy and negative impact of concomitant use of corticosteroids should be addressed in future prospective trials. To confirm our results, we plan to perform a pooled analysis with other tertiary clinics in order to achieve better statistical reliability.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Lewitzki V, Klement RJ, Kosmala R, et al. Accelerated hyperfractionated radiochemotherapy with temozolomide is equivalent to normofractionated radiochemotherapy in a retrospective analysis of patients with glioblastoma. Radiat Oncol. 2019. PMID: 31831026. doi:10.1186/s13014-019-1427-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。